Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

Abstract Introduction The leading professional organizations in the field of hematology have recommended severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) vaccination for all patients with hematologic malignancies notwithstanding efficacy concerns. Here we report a systematic literature r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The oncologist (Dayton, Ohio) Ročník 27; číslo 4; s. e357 - e361
Hlavní autoři: Guven, Deniz C, Sahin, Taha K, Akın, Serkan, Uckun, Fatih M
Médium: Journal Article
Jazyk:angličtina
Vydáno: US Oxford University Press 05.04.2022
Témata:
Antibodies, Viral
Blood diseases
Brief Communications
COVID-19 - prevention & control
COVID-19 Vaccines - therapeutic use
Development and progression
Diagnosis
Evaluation
Hematologic Neoplasms - complications
Humans
Immune response
Immunization
Leukemia
Patient outcomes
SARS-CoV-2
Seroconversion
Severe acute respiratory syndrome coronavirus 2
Vaccination
Turkey
COVID-19
hematological malignancies
SARS-CoV-2
vaccine
antibody
ISSN:1083-7159, 1549-490X, 1549-490X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Abstract Introduction The leading professional organizations in the field of hematology have recommended severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) vaccination for all patients with hematologic malignancies notwithstanding efficacy concerns. Here we report a systematic literature review regarding the antibody response to SARS-CoV-2 vaccination in patients with hematologic malignancies and its key determinants. Methods We conducted a systematic search of original articles evaluating the seroconversion rates with SARS-CoV-2 vaccines in hematological malignancies from the PubMed database published between April 1, 2021 and December 4, 2021. Calculated risk differences (RD) and 95% confidence intervals (CI) to compare seroconversion rates between patients with hematologic malignancies versus healthy control subjects used the Review Manager software, version 5.3. Results In our meta-analysis, we included 26 studies with control arms. After the first dose of vaccination, patients with hematologic malignancies had significantly lower seroconversion rates than controls (33.3% vs 74.9%; RD: −0.48%, 95% CI: −0.60%, −0.36%, P < .001). The seroconversion rates increased after the second dose, although a significant difference remained between these 2 groups (65.3% vs 97.8%; RD: −0.35%, 95% CI: −0.42%, −0.28%, P < .001). This difference in seroconversion rates was particularly pronounced for Chronic Lymphocytic Leukemia (CLL) patients (RD: −0.46%, 95% CI: −0.56, −0.37, P < .001), and for patients with B-lineage leukemia/lymphoma treated with anti-CD20 antibodies (RD: −0.70%, 95% CI: −0.88%, −0.51%, P < .001) or Bruton Tyrosine Kinase Inhibitors (BTKi; RD: −0.63%, 95% CI: −0.85%, −0.41%, P < .001). The RD was lower for patients under remission (RD: −0.10%, 95% CI: −0.18%, −0.02%, P = .01). Conclusion The seroconversion rates following SARS-CoV-2 vaccination in patients with hematologic malignancies, especially in CLL patients and patients treated with anti-CD20 antibodies or BTKi, were significantly lower than the seroconversion rates in healthy control subjects. Effective strategies capable of improving vaccine efficacy in these vulnerable patient populations are urgently needed.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1093/oncolo/oyac032